First New York Securities’s Oramed Pharmaceuticals ORMP Stock Holding History

First New York Securities’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-600	Closed	-$3.82K	–	524
2015 Q1	$3.82K	Buy	+600	New	+$2.9K	﹤0.01%	323
2014 Q1	–	Sell	-736	Closed	-$11K	–	452
2013 Q4	$11K	Buy	+736	New	+$5.67K	0.01%	240

Other funds holding ORMP

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

GIM

Greylin Investment Management Orange, Virginia $598M AUM 18.59% 1-Year Est. Return

TAM

Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return

HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FNBT

FineMark National Bank & Trust Fort Myers, Florida $3.2B AUM 18.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

First New York Securities's ORMP Position: Q2 2015 in Review

First New York Securities sold out of Oramed Pharmaceuticals (ORMP) in Q2 2015, closing a stake of 600 shares — an estimated $3.82K sold.

First New York Securities first reported a position in ORMP in Q4 2013 and held it in 2 quarters. The position peaked at $11K in Q4 2013. 15 funds tracked by Wall St. Rank hold ORMP as of Q2 2015.

First New York Securities reported no remaining Oramed Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
First New York Securities sold 600 Oramed Pharmaceuticals shares in Q2 2015, an estimated $3.82K.
First New York Securities first reported a position in Oramed Pharmaceuticals in Q4 2013 and held it in 2 quarters.
First New York Securities's Oramed Pharmaceuticals position peaked at $11K in Q4 2013.
15 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2015.

Based on First New York Securities's 13F filing for Q2 2015, filed 30 Jul 2015.